ATNF — ETHZilla Corporation Common Stock

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 4
• Website: https://180lifesciences.com

Latest SEC filings for ATNF

• 8-K — 2025-11-14
• 10-Q — 2025-11-14
• 8-K — 2025-10-29
• 8-K — 2025-10-27
• 8-K — 2025-10-23
• 8-K — 2025-10-15
• 8-K — 2025-10-08
• S-3ASR — 2025-10-06
• 8-K — 2025-09-30
• 8-K/A — 2025-09-25

Abrir análisis completo

Educational tool only — not investment advice.